Literature DB >> 180196

Genital herpetic infection in men and women: clinical course and effect of topical application of adenine arabinoside.

H G Adams, E A Benson, E R Alexander, L A Vontver, M A Remington, K K Holmes.   

Abstract

Sixty-three episodes of genital herpetic infection in 55 men and 45 episodes in 42 women were randomly assigned to topical treatment with 3% adenine arabinoside, topical treatment with placebo ointment, or no therapy. In addition, 10 episodes in women who were not randomly assigned to therapy were evaluated and followed. Clinical evaluation and viral cultures were done on day 3, day 8, and weekly thereafter until the lesions had healed. The natural clinical course of genital herpetic infection was defined in patients given placebo or no therapy. Patients with a history of previous genital herpetic infection had significantly less pain, few lesions, and shorter duration of illness and viral shedding than patients who had no history of previous genital infection with Herpesvirus. An unexpected finding was that 87% of women experiencing their first episode of genital herpetic infection had cervical cultures positive for Herpesvirus hominis, whereas only 4% of women with recurrent herpetic infection had a positive cervical culture. Treatment with 3% adenine arabinoside did not influence the course of either primary or recurrent genital infection with Herpesvirus.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 180196     DOI: 10.1093/infdis/133.supplement_2.a151

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  Recurrent genital herpes among women: symptomatic v. asymptomatic viral shedding.

Authors:  M C Rattray; L Corey; W C Reeves; L A Vontver; K K Holmes
Journal:  Br J Vener Dis       Date:  1978-08

3.  Genital herpes.

Authors:  F P Scappatura
Journal:  Can Fam Physician       Date:  1987-08       Impact factor: 3.275

4.  Resistance to vaginal or systemic infection with herpes simplex virus type 2.

Authors:  M C Breinig; L L Wright; M B McGeorge; P S Morahan
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

Review 5.  Antiviral agents: action and clinical use.

Authors:  T W Chang; D R Snydman
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

6.  Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis.

Authors:  J F Gephart; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  Evaluation of prodrugs of 9-beta-D-arabinofuranosyladenine for therapeutic efficacy in the topical treatment of genital herpesvirus infections in guinea pigs.

Authors:  W M Shannon; G Arnett; D C Baker; S D Kumar; W I Higuchi
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 8.  Antiviral agents: an update--Part I.

Authors:  S Bogger-Goren; P L Ogra
Journal:  Indian J Pediatr       Date:  1980 Sep-Oct       Impact factor: 1.967

9.  Predominance of herpes simplex virus type 1 from patients with genital herpes in Nova Scotia.

Authors:  Kevin R Forward; Spencer Hs Lee
Journal:  Can J Infect Dis       Date:  2003-03

Review 10.  Placebo interventions for all clinical conditions.

Authors:  Asbjørn Hróbjartsson; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.